1. Home
  2. ETNB vs ACMR Comparison

ETNB vs ACMR Comparison

Compare ETNB & ACMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • ACMR
  • Stock Information
  • Founded
  • ETNB 2018
  • ACMR 1998
  • Country
  • ETNB United States
  • ACMR United States
  • Employees
  • ETNB N/A
  • ACMR N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • ACMR Industrial Machinery/Components
  • Sector
  • ETNB Health Care
  • ACMR Technology
  • Exchange
  • ETNB Nasdaq
  • ACMR Nasdaq
  • Market Cap
  • ETNB 1.5B
  • ACMR 1.3B
  • IPO Year
  • ETNB 2019
  • ACMR 2017
  • Fundamental
  • Price
  • ETNB $9.23
  • ACMR $25.02
  • Analyst Decision
  • ETNB Strong Buy
  • ACMR Hold
  • Analyst Count
  • ETNB 8
  • ACMR 3
  • Target Price
  • ETNB $26.29
  • ACMR $27.00
  • AVG Volume (30 Days)
  • ETNB 1.6M
  • ACMR 1.3M
  • Earning Date
  • ETNB 08-07-2025
  • ACMR 08-06-2025
  • Dividend Yield
  • ETNB N/A
  • ACMR N/A
  • EPS Growth
  • ETNB N/A
  • ACMR 31.61
  • EPS
  • ETNB N/A
  • ACMR 1.66
  • Revenue
  • ETNB N/A
  • ACMR $815,166,000.00
  • Revenue This Year
  • ETNB N/A
  • ACMR $19.67
  • Revenue Next Year
  • ETNB N/A
  • ACMR $15.50
  • P/E Ratio
  • ETNB N/A
  • ACMR $15.10
  • Revenue Growth
  • ETNB N/A
  • ACMR 17.53
  • 52 Week Low
  • ETNB $4.16
  • ACMR $13.87
  • 52 Week High
  • ETNB $11.84
  • ACMR $32.54
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 45.00
  • ACMR 38.91
  • Support Level
  • ETNB $8.95
  • ACMR $23.59
  • Resistance Level
  • ETNB $9.50
  • ACMR $25.92
  • Average True Range (ATR)
  • ETNB 0.54
  • ACMR 1.34
  • MACD
  • ETNB -0.03
  • ACMR -0.57
  • Stochastic Oscillator
  • ETNB 42.60
  • ACMR 20.93

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About ACMR ACM Research Inc.

ACM Research Inc supplies advanced, innovative capital equipment developed for the global semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.

Share on Social Networks: